Engflag

Levocet-D+

Quick links to important sections

Levocet-D+

Levocet-D_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levocet-D+

Property Description
Active ingredients Levocetirizine and Phenylephrine
Form Oral Tablet
Pharmacological class Antihistamine and Decongestant
Common purpose Relief from allergy and cold symptoms
Origin Synthetic

What Type of Medicine is Levocet-D+?

Levocet-D+ is a fixed-dose combination (FDC) medicine containing a potent antihistamine and a nasal decongestant. It is classified as both a Histamine H1 Receptor Antagonist and an Adrenergic Alpha-1 Agonist. This specific pairing is clinically recognized for its effectiveness in alleviating the dual symptoms of allergy-related itching and persistent nasal blockage. This FDC is designed for patient convenience, as it provides comprehensive relief that targets symptoms both inside the nasal passages and across the body.

What Active Ingredients are in Levocet-D+?

The two primary active ingredients are Levocetirizine and Phenylephrine, both of which are small-molecule, synthetic compounds. Levocetirizine is favored as a second-generation antihistamine, supported by pharmacological studies demonstrating it is generally less sedating compared to older agents. This component works to control allergic reactions like sneezing and watery eyes.

Phenylephrine acts as a decongestant, targeting the swollen tissues in the nose. This combination is a frequently prescribed formula available under several trade names globally, demonstrating its established utility in acute cold and allergy care. This precise formulation, delivered typically as an oral tablet, ensures patients receive a defined, co-administered dose of both the allergy reliever and the congestion reliever for systemic symptom management.

Levocet-D+ Dosage Form

Levocet-D+ is typically supplied as an oral tablet, which is the standard route of administration for this combination. This dosage form allows the active ingredients to be absorbed systemically (through the bloodstream) from the digestive tract, ensuring the anti-allergic and decongestant properties work throughout the body and nasal passages. The tablet formulation is created using various inactive ingredients (excipients) to ensure stability, accurate dosing, and proper absorption.

What side effects are possible with Levocet-D+?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse effects and safety constraints for the active ingredients in Levocet-D+ (Levocetirizine and Phenylephrine), strictly based on government regulatory labeling, such as the FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).

Adverse Reaction Scope

Category Official Regulatory Documentation Summary
Frequency Classification Common effects include Somnolence, Fatigue, Dry Mouth, and Nasopharyngitis. Not Known (post-marketing) frequency includes events like Hypersensitivity and Convulsion.
System-Organ Classes Involved Documented categories include Nervous System Disorders (e.g., headache, somnolence, convulsion), Psychiatric Disorders (e.g., aggression, depression, insomnia), Gastrointestinal Disorders (e.g., dry mouth, nausea), and Cardiac Disorders (e.g., tachycardia).
Serious Adverse Reactions Officially documented serious reactions include Hypersensitivity (including Anaphylaxis), Convulsions/Seizures, and rare post-marketing reports of Suicidal Ideation. Phenylephrine use is associated with potential Cardiac Arrhythmias or Hypertensive Crisis.
Population-Specific Restrictions The medication is contraindicated in patients with severe renal impairment (end-stage renal disease, CLcr < 10 mL/min). Caution is advised in patients with predisposing factors for urinary retention or a history of epilepsy due to the potential for seizure aggravation.
Exposure-Related Patterns Rebound Pruritus (intense itching) is reported following the discontinuation of long-term daily use of Levocetirizine. The Phenylephrine component may be associated with rhinitis medicamentosa (rebound nasal congestion) with prolonged use.

Safety-Related Restrictions

  • Hypersensitivity: Contraindicated in patients with known hypersensitivity to the active substances or any piperazine derivatives (e.g., Cetirizine, Hydroxyzine).
  • Renal Contraindication: Contraindicated in individuals with severe renal impairment (CLcr < 10 mL/min) and pediatric patients with impaired renal function.

Connection to the overall safety profile:

This documentation structures the potential risks by formally classifying adverse reactions by their frequency and the body system affected. This regulatory framework clearly identifies both common, expected effects and rare, serious events, while defining mandatory safety limits and contraindications based on patient health status.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

Overdosage with the combination of Levocetirizine and Phenylephrine is documented in regulatory sources as potentially affecting the Central Nervous System (CNS) and the Cardiovascular System. Manifestations are dual in nature, reflecting the effects of each active ingredient.

Documented Overdose Presentations and Scope:

  • CNS Effects (Levocetirizine): The primary sign in adults is often somnolence (drowsiness). In pediatric patients, regulatory labeling notes that initial agitation or restlessness may occur before progressing to potential CNS depression.
  • Cardiovascular Effects (Phenylephrine): High doses are officially associated with sympathetic overstimulation, risking severe cardiovascular symptoms such as hypertensive crisis and fast or irregular heart rhythms (arrhythmias).

Required Emergency Actions:

  • Immediate Medical Attention: Seek immediate medical attention for any suspected overdose. Urgent assistance is required for severe symptoms like loss of consciousness, seizures, or signs of severe cardiac distress.
  • Management: Management is defined as symptomatic and supportive treatment. Official information confirms that no specific antidote is known. Procedures such as gastric lavage or use of activated charcoal may be considered by medical professionals, where appropriate, to limit absorption.

Therapeutic Uses of Levocet-D+

What Levocet-D+ Treats: Main Uses and Benefits

This combination medication is applied across domains where additional symptomatic support is needed and is commonly used to provide symptomatic support for Allergic Rhinitis (commonly known as Hay Fever), which includes conditions involving episodic or fluctuating manifestations. It is commonly used to help manage symptom clusters that may become intense or disruptive, such as sneezing, an itchy and runny nose, and ocular discomfort. The medication is generally used to help with these symptoms.

Levocet-D+ is also relevant for easing symptoms related to inflammatory or irritative states in the nasal passages, such as the nasal and sinus congestion associated with allergies and the common cold. Its uses are relevant in situations involving certain distressing symptoms, including those from urticaria (hives) and, where appropriate, symptomatic assistance when nasal inflammation contributes to middle ear discomfort (Eustachian Tube Dysfunction).

“It provides support that helps ease the overall symptom burden, particularly when symptoms interfere with routine activities.”

It is applied during phases of increased distress or discomfort, supporting patients during symptom fluctuations and assisting with maintaining functional stability.

Quick Fact: Focus: Nasal Congestion and Systemic Itching Symptom Support

Regulatory References

  1. NIH MedlinePlus overview on Levocetirizine

Eligibility and Restrictions for Use

The eligibility for Levocet-D+ (Levocetirizine and Phenylephrine FDC) is determined by official constraints related to age, cardiovascular health, and kidney function, as documented in regulatory labeling.

Populations Who Must Not Use Levocet-D+ (Contraindications)

  • Patients with known Hypersensitivity to levocetirizine, cetirizine, or any components of the tablet.
  • Patients with End-Stage Renal Disease (creatinine clearance mathbf< 10 mL/min) or those undergoing Hemodialysis.
  • Children 6 months to 11 years of age with diagnosed Impaired Renal Function.
  • Individuals with Severe Coronary Artery Disease or Severe/Uncontrolled Hypertension (due to Phenylephrine content).

Conditional Use and Restrictions

  • Age Limits: The combination tablet is not recommended for children below 12 years of age. Use is not established in infants younger than 6 months.
  • Renal Impairment: Adults and adolescents ge 12 years with mild, moderate, or severe kidney impairment require a dose adjustment based on the severity of the impairment.
  • Comorbidities: Caution is advised for patients with predisposing factors for Urinary Retention (such as prostatic hyperplasia), Hyperthyroidism, Glaucoma, or a history of Epilepsy.
  • Pregnancy/Lactation: Use during pregnancy is considered conditional (only if clearly needed). Use while breastfeeding is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction profile for Levocet-D+, based strictly on government regulatory documents (e.g., FDA Prescribing Information, EMA SmPC).

Interaction Type Details Based on Regulatory Labeling Supporting Component
Formal Contraindication Co-use with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited, including for 14 days after their discontinuation. Phenylephrine
Use is contraindicated in patients with end-stage renal disease ( CrCl < 10 mL/min). Levocetirizine
Pharmacodynamic Risk Concomitant use with Alcohol (Ethanol) and other Central Nervous System (CNS) Depressants (e.g., sedatives) can lead to additive CNS depression and reduced alertness. Levocetirizine
Caution is officially advised regarding co-administration with other Sympathomimetic Agents, due to the potential for increased cardiovascular effects. Phenylephrine
Pharmacokinetic Note The use of Theophylline is documented to cause a small, measurable decrease in the clearance of Levocetirizine. Levocetirizine

Official Interaction Statements:

  • The most severe restriction is the contraindication against combining Levocet-D+ with MAOIs.
  • The profile documents that CNS Depressants and Alcohol pose a risk of pharmacodynamic reinforcement of sedative effects.
  • No specific timing-based separation rules are explicitly mandated in the regulatory documents for this combination.
  • The interaction structure includes a population-specific constraint: patients with severe renal impairment should not receive Levocetirizine due to significantly reduced drug clearance.

This structure reflects the defined regulatory constraints, primarily concerning the risks of additive central and cardiovascular effects, and pharmacokinetic changes in specific populations.

Mechanism of Action

Levocet-D+ functions through a dual pharmacodynamic mechanism involving histamine H1 receptor antagonism and alpha1 -adrenergic-receptor agonism. Levocetirizine, the R-enantiomer of cetirizine, competitively and selectively binds to peripheral H1 receptors, thereby preventing the binding and action of endogenous histamine. This molecular blockade inhibits the H1 -receptor-mediated activation of intracellular pathways, including those coupled to Gq proteins, and attenuates the release of preformed inflammatory mediators from mast cells. Pseudoephedrine acts as a direct agonist on alpha1 -adrenergic receptors and indirectly as a sympathomimetic amine by promoting norepinephrine release from presynaptic terminals. Agonism of the alpha1 receptors on vascular smooth muscle results in cellular contraction and subsequent vasoconstriction within the nasal mucosa. This vasoconstriction decreases vascular permeability and reduces fluid exudation into the surrounding tissue. The combined mechanisms provide complementary biological modulation of both H1-mediated signaling and sympathetic vascular tone.

Dosage and Administration Information

The administration of the Levocetirizine/Phenylephrine combination product (Levocet-D+) and its components follows established clinical parameters.

Administration Scope

Guideline Instruction
Route of Administration Oral administration as a tablet.
Dosing Frequency The Levocetirizine component is typically dosed once daily in the evening, though the combination product containing Phenylephrine may require a twice-daily schedule.
Timing Relative to Food The tablet may be taken with or without food.
Preparation Tablets should be swallowed whole with liquid. They should not be crushed unless specified for dose splitting of a scored tablet.
Maximum Dose The maximum recommended daily dose for the Levocetirizine component in adults with normal renal function is 5 mg.

Population-Specific Dosing (Levocetirizine Component)

Dosage adjustments are utilized based on renal function for patients aged 12 years and older.

Creatinine Clearance (CLCR) Recommended Levocetirizine Dose
Mild Impairment (50–80 mL/min) 2.5 mg once daily
Moderate Impairment (30–50 mL/min) 2.5 mg once every other day
Severe Impairment (10–30 mL/min) 2.5 mg twice weekly (every 3-4 days)

Patients with end-stage renal disease (CLCR < 10 mL/min) or those undergoing hemodialysis should not receive the Levocetirizine component. No dose adjustment is required for patients with solely hepatic impairment.

Missed Dose Instructions

If a dose is missed, it should be taken when remembered, but two doses must not be taken at the same time to compensate for a missed dose.

Recent Clinical Evidence

Recent Clinical Evidence

Research regarding Levocet-D+ primarily focuses on its use in managing symptoms associated with seasonal and perennial allergic rhinitis, as well as chronic idiopathic urticaria. These conditions are typically characterized by nasal congestion, sneezing, watery eyes, and itching.

Studies examined the speed of symptom relief, and research evaluated the potential for a change in symptoms of acute pain. Research reports describe the hypothesized method of action through inflammation pathways. Research investigated if it was associated with reduced pain and swelling. Studies explored various clinical outcomes.

Efficacy and Duration of Effect

Clinical trials have examined the efficacy of Levocet-D+ components in reducing symptoms compared to placebo. Studies noted whether pain levels were lower compared to placebo in trials lasting up to six weeks, reflecting the duration of the investigation. One study evaluated specific dosage amounts and their relation to observed outcomes. The combination component is generally studied for its effect on reducing nasal congestion specifically, a key symptom in allergic rhinitis.

Safety Profile and Research Context

Safety studies examined a broad range of participants. Research noted that individuals with specific co-existing conditions, such as liver issues, were typically excluded from trials, or that special caution was applied in those subgroups. Studies also examined whether the combination of ingredients was associated with overall outcome, particularly regarding potential changes in heart rate or blood pressure due to the decongestant component.

Frequently Asked Questions (FAQ)

Common questions about Levocet-D+ (FAQ)

Q: How quickly does Levocet-D+ start working?

A: Clinical studies involving the decongestant component indicate that relief from nasal airways resistance may begin within 15 to 20 minutes, with the peak effect typically observed in one to two hours. The antihistamine component, Levocetirizine, also generally reaches its highest concentration in the bloodstream in about one hour. Individual response times may vary.

Q: Can children under 12 take Levocet-D+?

A: According to the official product information, the combination tablet is not recommended for use in children below 12 years of age. Use in infants younger than 6 months is not established in the regulatory information. Official labeling also states that children with impaired kidney function should not use this medication.

Q: How does Levocet-D+ relieve nasal congestion and allergy symptoms?

A: This product is a combination medicine with a dual mechanism of action. One active component is an antihistamine, which works by blocking the action of certain chemicals that are linked to common allergy symptoms such as sneezing and itching. The other component is a decongestant that helps narrow the blood vessels in the nasal passages to relieve congestion.

Q: What are the restrictions for pregnant or breastfeeding women?

A: The regulatory label indicates that use during pregnancy is conditional and is generally reserved for situations where a potential benefit is considered to outweigh the potential risks. Use while breastfeeding is generally not recommended because official product information confirms that the antihistamine component is known to be excreted in human milk.

Q: Is Levocet-D+ available over-the-counter or does it require a prescription?

A: The two active components, Levocetirizine and Phenylephrine, are offered in various forms globally. Depending on the specific dose, formulation, and local government regulation, this product may be offered as both a prescription-only medicine or available for purchase over-the-counter.

Q: What is the recommended maximum duration of use for the decongestant component?

A: Official labeling advises that the decongestant component is intended for use over a short period. The regulatory documents warn against using any nasal decongestant for prolonged periods, as this carries a risk of leading to a condition known as rebound nasal congestion.

How should Levocet-D+ be stored and disposed of?

How to Store and Dispose of Levocet-D+

The official storage and disposal guidelines for Levocet-D+ (Levocetirizine and Phenylephrine oral tablet) ensure the medicine maintains its stability and minimize environmental impact.

Official Storage Requirements

  • Temperature and Protection: Store the tablets below 30 C (or 25 C, depending on the labeled region), and do not freeze the product.
  • Packaging Rules: The medicine must be kept in its original container or packet, which should be tightly closed to protect the contents from moisture and light.
  • Safety Rule: A mandatory requirement is to keep this medicine out of the sight and reach of children at all times.
  • Stability Constraint: The product must not be used after the expiry date (EXP) printed on the packaging.

Official Disposal Requirements

  • Do not dispose of any unused or expired Levocet-D+ through household waste or by flushing it down the wastewater/sewer system.
  • Proper Disposal: Disposal must follow the instructions provided by a pharmacist or national/local regulatory body, in accordance with local pharmaceutical and environmental requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Levocet-D+ found in:

A-Z Index: